Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Emil Valle

Gastroenterology Reston, VA Medical Doctor

NPI 1497711238 CMS profile 248828

11440 Commerce Park Dr, Ll4, Reston, VA 20191

Open in the dashboard

General payments

$12,757

689 records reported · program years 2019–2025

Research payments

$7,977

Paid to them · 9 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$175,246 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Emil Valle of Reston, VA is reported in the CMS Open Payments database as having received $12,757 across 689 general payments and $7,977 in research payments paid to them. Separately, studies naming them as principal investigator received $175,246 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,100 147
2024 General $2,927 131
2023 General $1,918 103
2022 General $2,125 120
2021 General $719 39
2021 Research $5,417 4
2020 General $322 25
2020 Research $422 3
2019 General $1,646 124
2019 Research $2,138 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emil Valle
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Emil Valle were reported at $3,100. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Emil Valle Gastroenterology median Middle half National median
2019 $1,646 $417 $126–$1,100 $163
2020 $322 $224 $74–$624 $114
2021 $719 $352 $106–$1,054 $132
2022 $2,125 $448 $129–$1,270 $149
2023 $1,918 $533 $150–$1,390 $160
2024 $2,927 $605 $160–$1,606 $164
2025 $3,100 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,231 228 payments
  2. Janssen Biotech, Inc. $1,327 52 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,103 73 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $962 61 payments
  5. Pfizer Inc. $735 46 payments
  6. Celgene Corporation $662 54 payments
  7. Gilead Sciences, Inc. $568 27 payments
  8. Boston Scientific Corporation $567 7 payments
  9. QOL Medical, LLC $377 17 payments
  10. Regeneron Healthcare Solutions, Inc. $349 15 payments
  11. Other $2,877 109 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,487 678 payments
  2. Education $270 11 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,316 72 payments
  2. RINVOQ $1,143 73 payments
  3. ZEPOSIA $891 56 payments
  4. STELARA $790 32 payments
  5. HUMIRA $759 71 payments
  6. ENTYVIO $720 40 payments
  7. SKYRIZI $706 44 payments
  8. TREMFYA $655 20 payments
  9. CREON $631 43 payments
  10. XELJANZ $590 38 payments
  11. Other $6,183 313 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $7,977 9 payments

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

327

Median for Gastroenterology: 569

Drug cost

$330,963

Median for Gastroenterology: $104,976

Branded share of claims

30.3%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 23 $189,780
Humira(Cf) Pen Adalimumab Brand 13 $86,397
Creon Lipase/Protease/Amylase Brand 12 $41,603
Dexlansoprazole Dr Dexlansoprazole Brand 16 $6,787
Rabeprazole Sodium Generic 81 $2,578
Budesonide Dr Budesonide Brand 12 $837
Esomeprazole Magnesium Generic 19 $826
Pantoprazole Sodium Generic 71 $820
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 11 $639
Famotidine Generic 35 $299

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$235,039

Of which drugs: $126,749

Medicare patients

531

Average age 75

Services billed

7,866

320 women, 211 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 52%
Ischemic heart disease 31%
Diabetes 27%
Chronic kidney disease 24%
Osteoporosis 21%
Atrial fibrillation 20%
Depression 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $318
$318 — —
TREMFYA
  • Janssen Biotech, Inc. $209
$209 — —
RINVOQ
  • AbbVie, Inc. $196
$196 — —
ZEPOSIA
  • Celgene Corporation $171
$171 — —
SKYRIZI
  • AbbVie, Inc. $157
$157 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

698 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record